Nieuwsfeed
- Patient Engagement Collaborative
- UK says it won't purchase AstraZeneca's Covid treatment due to 'insufficient' Omicron data — reports
- Resilience partners with the Mayo Clinic to manufacture rare and complex disease drugs
- Gilead's Trodelvy scores 'surprise' OS win in metastatic breast cancer, but data will wait for an upcoming conference
- New Legislation Overhauls Medicare Drug Pricing and Benefits
- Moderna's bivalent Omicron vaccine secures regulatory OK in UK
- Emergent nets itself more trouble as it receives a warning letter from the FDA
- Biologics Electronic Reading Room (eFOI)
- The Canadian life sciences hub that may not be on your FDI radar (but should be)
- French pharma exec says he lied to FDA in attempt to steal a Novartis weight loss drug
- Gilead commits millions more for HIV health equity efforts in southern cities
- Cloud hiring levels in the clinical trial operations industry rose to a year-high in July 2022
- Consumer Updates
- Novavax COVID-19 Vaccine, Adjuvanted
- An antibiotics player axes staff in wake of PhIII fail; Horizon to fund antibody development, with option to buy
- After last year's public rejection, BrainStorm to give ALS cell therapy another shot despite still flunking a re-analyzed PhIII
- Pyxis taking scalpel to preclinical pipeline, stops development on half — for now
- Atai prunes pipeline, drops out of partnerships as it takes on $175M loan and focuses on looming data readouts
- After a huge sale, 'Pharma Bro' Martin Shkreli’s crypto token plummets
- Ideaya stock slashed after GSK punts an option
- Clinical trial results for $3.2 billion Covid drug are missing in action
- What’s New for Biologics
- Pfizer CEO Albert Bourla is putting his Covid-19 vaccine to a personal test. And so far, so good
- PREA Non-Compliance Letters
- Size and shape of human mesenchymal stem cells may predict future biochemical behavior potentially linked to supporting bone growth
- Clene claims its PhII MS trial, half its intended size, cleared the primary goal. But can the biotech afford PhIII?
- You can add a colorful Australian mining tycoon to the list of billionaires betting on biotech
- Field Safety Notices: 8 to 12 August 2022
- David Baker lab spinout scores seed funding to build a biosensor from engineered protein
- House Passes Inflation Reduction Act, Marks a New Era for Climate Policy
- The Blue Guide 2022 update – new elements regarding applicability of EU law on products
- Enhertu strikes again with a PhIII success in another breast cancer population
- Carlyle finds its first big biotech bet after teaming with Abingworth
- Sometimes you win. Sometimes you lose. And sometimes it's just another PhIII canakinumab fail
- Regulatory approval of Spikevax bivalent Original/Omicron booster vaccine
- First bivalent COVID-19 booster vaccine approved by UK medicines regulator
- A tale of (3)2 retraction notices: On publishers, paper mill products, and the sleuths that find them
- Keeping Publishing Infrastructure Independent
- We stellen graag aan je voor: Joran van Apeldoorn
- Revealed: the drug development companies best positioned to weather future industry disruption
- Can AI remedy the growing pains of digital biomarker development?
- FDA offers "Snapshot" Feature for Clinical and Development Guidelines
- UK changes SUSAR Reporting for IMPs
- Landmark Drug Pricing Bill Set to Become Law; HP&M Releases Summary Slide Deck
- Article 16 – some loose ends in the Regulations…
- Weekend reads: Underage sex comic study removed following outrage; postdoc claims retaliation; plagiarism in COVID-19 papers
- FDA Roundup: August 12, 2022
- Almac Group Announces $65M Expansion of North American Headquarters
- Examining the Current Value of ClinicalTrials.gov Listings for Patients and the Public
- Iran is a leader in Phase III clinical trials in women’s health
Op de hoogte blijven van actueel nieuws, bijeenkomsten en publieke consultaties